Drug Profile
Taribavirin
Alternative Names: AVS-206; ICN-3142; Taribavirin hydrochloride; ViramidineLatest Information Update: 19 Jul 2018
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Kadmon Pharmaceuticals
- Class Antivirals; Ribonucleosides; Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 01 Nov 2012 No development reported - Phase-III for Hepatitis C in USA (PO)
- 04 Nov 2010 Taribavirin is in active development for Hepatitis C in USA